Brief: Idera Pharmaceuticals Presents ILLUMINATE-101 Data at the AACR 2019 Annual Meeting

Aceragen

02/04/2019 12:18

April 2 (Reuters) - Idera Pharmaceuticals Inc  IDRA.O :
    * IDERA PHARMACEUTICALS PRESENTS ILLUMINATE-101 DATA
DEMONSTRATING
TILSOTOLIMOD ACTIVATES INNATE AND ADAPTIVE IMMUNITY AS
MONOTHERAPY IN PATIENTS WITH REFRACTORY SOLID TUMORS AT THE
AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) 2019 ANNUAL
MEETING
    * IDERA PHARMACEUTICALS INC - NO DOSE LIMITING TOXICITIES OR
TREATMENT-RELATED ADVERSE EVENTS WERE OBSERVED IN ILLUMINATE-101
PHASE 1 STUDY
    * IDERA PHARMACEUTICALS - NO TREATMENT-EMERGENT ADVERSE
EVENTS
LEADING TO TREATMENT OR STUDY DISCONTINUATION OR DEATH OCCURRED
IN ILLUMINATE-101 STUDY

Source text for Eikon:  ID:nGNX47W6xT 
Further company coverage:  IDRA.O 

 ((Reuters.Briefs@thomsonreuters.com;))